Australian pharmaceutical research company Pharmaxis has teamed up with the University of Western Australia (UWA) to start a world-first clinical trial to investigate a cream to stop scars forming after trauma, particularly following burn injuries.
Australian pharmaceutical research company Pharmaxis has teamed up with the University of Western Australia (UWA) to start a world-first clinical trial to investigate a cream to stop scars forming after trauma, particularly following burn injuries.
The trial will be led by prominent surgeon and burns expert Professor Fiona Wood and her team from UWA and researchers from Fiona Stanley Hospital in Murdoch, Western Australia.
Together they will test Pharmaxis’s topical discovery, known as PXS-6302, which has shown promising pre-clinical results in restraining the enzymes that play a significant role in the development of scar tissue.
“Scar-less healing is the vision that has motivated our work over many decades.”
“This new compound may potentially avoid the need for invasive procedures such as further surgery or laser procedures.”
The pioneering human trial will first evaluate the safety and tolerability of the product in healthy volunteers before conducting further trials in burns and surgical patients.
